Retatrutide 10mg (LY3437943)
Research Use Only
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Purity / Result
>99.80% +/- 0.18%
Mass / Quantity
11.07 mg
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Retatrutide is a novel triple-hormone receptor agonist peptide for metabolic research applications. This 10mg vial is ideal for initial research protocols and dose-response studies. Each batch is HPLC-verified for purity and identity.
Frequently Bought Together
Retatrutide 10mg
10mg
$64 USD
Bundle & Save
$114 USD
Save $4 USD
$149 USD
Save $14 USD
$244 USD
Save $39 USD
$344 USD
Save $69 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Explore Research
Peptide Tools
Someone in Melbourne, AU purchased
GLOW 70mg
18 minutes ago